Progresses of mycobacteriophage-based Mycobacterium tuberculosis detection

Zichen, Liu; Guo, Siyao; Ji, Mengzhi; Sun, Kaili; Liu, Guohong; Fan, Xiangyu

doi:10.32604/biocell.2020.011713

Cited by 4 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mycobacteriophage, a virus that infects mycobacteria, is pre-incubated with the test anti-TB drug before adding MTB, which forms plaques on the agar surface when MTB is resistant. 75 Mycobacteriophage-based susceptibility assays are divided into two types; the first is the phage amplified biologically (PhaB) assay, which employs sensitive host bacteria such as M. smegmatis to multiply offspring phages capable of infecting M. tuberculosis. 76 FASTPlaqueTBTM, a commercially available kit, offers greater sensitivity and specificity than standard MTB diagnostic methods and can more precisely represent MTB activity, metabolic features, and the proportion of drugresistant bacteria.…”

Section: Phage-based Susceptibility Testingmentioning

confidence: 99%

“…Conversely, it might be technically challenging, labour-intensive and have significant failure rates with uninterpretable results. 65,75,76 Dio-TK culture system Dio-TK Culture System, a rapidly automated colourimetric technique, is commercially available to isolate mycobacteria from clinical samples. 78 This system contains dye as an indicator, and colour variations in the media reveal the metabolic activity due to mycobacterial growth.…”

Section: Phage-based Susceptibility Testingmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review

Tawfick,

Badawy,

Taleb

et al. 2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Tuberculosis (TB) is a significant public health challenge, especially in developing nations. Developing a TB eradication strategy is hampered by the global health concern of drug-resistant (DR) TB. Effective patient treatment, preventing TB transfer and avoiding the upsurge of DR strains depend primarily on the timely and accurate identification of DR TB. Due to inadequate sensitivity, the necessity of trained laboratory personnel, the sluggish growth pattern of Mycobacterium bacilli in culture, and the small number of bacilli that are usually found in extrapulmonary TB samples, TB diagnosis is still tricky in clinical practice. Although mycobacterial culture is the gold standard to identify TB and determine drug resistance, it takes 2 to 8 weeks to develop. Despite their high cost, nucleic acid amplification tests (NAATs) and whole-genome sequencing (WGS) are the commonly employed molecular-based methods for diagnosing and identifying TB. The WHO suggested the GeneXpert MTB/RIF to identify TB and detect resistance to rifampicin. In comparison, numerous molecular techniques were developed, including allele-specific PCR (MAS-PCR), solid-phase hybridization, real-time PCR (RT-PCR) and droplet digital PCR-based technique (DDPCR). This manuscript is intended to overview the current approaches for the phenotypic and genotypic diagnosis of TB disease and identifying resistance to antitubercular drugs depending on recently published articles, WHO and CDC reports, and commercially available diagnostic tools.

show abstract

Section: Phage-based Susceptibility Testingmentioning

confidence: 99%

Section: Phage-based Susceptibility Testingmentioning

confidence: 99%

Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review

Tawfick,

Badawy,

Taleb

et al. 2023

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Recent PRA endeavors have focused on facilitating the technology by creating affordable detection equipment [17]. PhAB assays and PRAs have been apprised in detail elsewhere [18][19][20]. Therefore, we sought to evaluate other, less explored, phage-based approaches.…”

Section: Mycobacteriophages As Diagnosticsmentioning

confidence: 99%

“…Therefore, we sought to evaluate other, less explored, phage-based approaches. For more in-depth detail on PhAB and PRA methodologies, readers are encouraged to see the FASTPlaque TB™ (Biotech Labs Ltd., Ipswich, UK) [16,21] and proof-of-concept luciferase reporter phage assays [20,22]. Table 1 presents a summary of commercial and published phage technologies that have been used to detect mycobacteria.…”

Section: Mycobacteriophages As Diagnosticsmentioning

confidence: 99%

“…One way to ease this transition is to demonstrate the assay with clinical samples. Many proofof-concept studies utilized clinical samples, improving confidence in their applicability [20,27,29,31,34]. A good example of proof-of-concept translation can be seen when the phage real-time PCR assay developed by Pholwat et al [27] was implemented in a Thailand reference laboratory [35].…”

Section: Mycobacteriophages As Diagnosticsmentioning

confidence: 99%

See 1 more Smart Citation

Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment

et al. 2021

View full text Add to dashboard Cite

Mycobacterium tuberculosis and other non-tuberculous mycobacteria are responsible for a variety of different infections affecting millions of patients worldwide. Their diagnosis is often problematic and delayed until late in the course of disease, requiring a high index of suspicion and the combined efforts of clinical and laboratory colleagues. Molecular methods, such as PCR platforms, are available, but expensive, and with limited sensitivity in the case of paucibacillary disease. Treatment of mycobacterial infections is also challenging, typically requiring months of multiple and combined antibiotics, with associated side effects and toxicities. The presence of innate and acquired drug resistance further complicates the picture, with dramatic cases without effective treatment options. Bacteriophages (viruses that infect bacteria) have been used for decades in Eastern Europe for the treatment of common bacterial infections, but there is limited clinical experience of their use in mycobacterial infections. More recently, bacteriophages’ clinical utility has been re-visited and their use has been successfully demonstrated both as diagnostic and treatment options. This review will focus specifically on how mycobacteriophages have been used recently in the diagnosis and treatment of different mycobacterial infections, as potential emerging technologies, and as an alternative treatment option.

show abstract

Fluorescent lateral flow assay strip for Mycobacterium tuberculosis and Mycobacterium smegmatis based on mycobacteriophage tail protein and aptamer

Yue,

Yang,

et al. 2025

Talanta

View full text Add to dashboard Cite

Progresses of mycobacteriophage-based Mycobacterium tuberculosis detection

Cited by 4 publications

References 58 publications

Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review

Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review

Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment

Fluorescent lateral flow assay strip for Mycobacterium tuberculosis and Mycobacterium smegmatis based on mycobacteriophage tail protein and aptamer

Contact Info

Product

Resources

About